Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus?

Publisher： Karger

E-ISSN： 1421-9832|214|4|275-277

ISSN： 1018-8665

Source： Dermatology, Vol.214, Iss.4, 2007-04, pp. : 275-277

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

By  

Dermatology, Vol. 214, Iss. 4, 2007-04 ,pp. : 310-318

Karger

Access to resources Recommend Favorite

Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab

By  

Dermatology, Vol. 215, Iss. 3, 2007-09 ,pp. : 252-255

Karger

Access to resources Recommend Favorite

Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient

By  

Dermatology, Vol. 218, Iss. 1, 2008-10 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy

By  

Dermatology, Vol. 206, Iss. 4, 2003-06 ,pp. : 388-390

Karger

Access to resources Recommend Favorite

Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab

By  

Dermatology, Vol. 218, Iss. 3, 2008-12 ,pp. : 237-245

Karger

Access to resources Recommend Favorite